H2 Core Ag News - 0ND9

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Provides Private Placement Update

Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or...

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Announces Withdrawal of Marketed Public Offering

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov...

L'OCRCVM permet la reprise de la négociation - ACOG

L'OCRCVM permet la reprise de la négociation - ACOG Canada NewsWire VANCOUVER, BC, le 18 nov. 2022 VANCOUVER, BC, le 18 nov. 2022 /CNW/...

IIROC Trading Resumption - ACOG

IIROC Trading Resumption - ACOG Canada NewsWire VANCOUVER, BC, Nov. 18, 2022 VANCOUVER, BC, Nov. 18, 2022 /CNW/ - Trading resumes in: Company:...

Suspension de la négociation par l'OCRCVM - ACOG

Suspension de la négociation par l'OCRCVM - ACOG Canada NewsWire VANCOUVER, BC, le 17 nov. 2022 VANCOUVER, BC, le 17 nov. 2022 /CNW/...

IIROC Trading Halt - ACOG

IIROC Trading Halt - ACOG Canada NewsWire VANCOUVER, BC, Nov. 17, 2022 VANCOUVER, BC, Nov. 17, 2022 /CNW/ - The following issues have been halted...

Alpha Cognition Announces Marketed Offering

NOT FOR DISSEMINATION IN THE UNITED STATESOR THROUGH U.S. NEWSWIRE SERVICES VANCOUVER, British Columbia, Nov...

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing...

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

H2 Core Ag (0ND9)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

0ND9 News

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Alpha Cognition Provides Private Placement Update

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Withdrawal of Marketed Public Offering

L'OCRCVM permet la reprise de la négociation - ACOG

IIROC Trading Resumption - ACOG

Suspension de la négociation par l'OCRCVM - ACOG

IIROC Trading Halt - ACOG

Alpha Cognition Announces Marketed Offering

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

0ND9 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

H2 Core Ag (0ND9) News

H2 Core Ag (0ND9)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

0ND9 News

Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Alpha Cognition Provides Private Placement Update

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Withdrawal of Marketed Public Offering

L'OCRCVM permet la reprise de la négociation - ACOG

IIROC Trading Resumption - ACOG

Suspension de la négociation par l'OCRCVM - ACOG

IIROC Trading Halt - ACOG

Alpha Cognition Announces Marketed Offering

Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update

Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease

Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease

Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd

Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602

0ND9 Discussion

Your Recent History